214 related articles for article (PubMed ID: 25816330)
1. Eicosapentaenoic acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice.
Konuma K; Itoh M; Suganami T; Kanai S; Nakagawa N; Sakai T; Kawano H; Hara M; Kojima S; Izumi Y; Ogawa Y
PLoS One; 2015; 10(3):e0121528. PubMed ID: 25816330
[TBL] [Abstract][Full Text] [Related]
2. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
Goto T; Itoh M; Suganami T; Kanai S; Shirakawa I; Sakai T; Asakawa M; Yoneyama T; Kai T; Ogawa Y
Sci Rep; 2018 May; 8(1):8157. PubMed ID: 29802399
[TBL] [Abstract][Full Text] [Related]
3. CD11c+ resident macrophages drive hepatocyte death-triggered liver fibrosis in a murine model of nonalcoholic steatohepatitis.
Itoh M; Suganami T; Kato H; Kanai S; Shirakawa I; Sakai T; Goto T; Asakawa M; Hidaka I; Sakugawa H; Ohnishi K; Komohara Y; Asano K; Sakaida I; Tanaka M; Ogawa Y
JCI Insight; 2017 Nov; 2(22):. PubMed ID: 29202448
[TBL] [Abstract][Full Text] [Related]
4. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis.
Komiya C; Tanaka M; Tsuchiya K; Shimazu N; Mori K; Furuke S; Miyachi Y; Shiba K; Yamaguchi S; Ikeda K; Ochi K; Nakabayashi K; Hata KI; Itoh M; Suganami T; Ogawa Y
Sci Rep; 2017 Mar; 7():44754. PubMed ID: 28303974
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of hepatic function using dynamic contrast-enhanced magnetic resonance imaging in melanocortin 4 receptor-deficient mice as a model of nonalcoholic steatohepatitis.
Yamada T; Kashiwagi Y; Rokugawa T; Kato H; Konishi H; Hamada T; Nagai R; Masago Y; Itoh M; Suganami T; Ogawa Y; Abe K
Magn Reson Imaging; 2019 Apr; 57():210-217. PubMed ID: 30465867
[TBL] [Abstract][Full Text] [Related]
6. Hepatic crown-like structure: a unique histological feature in non-alcoholic steatohepatitis in mice and humans.
Itoh M; Kato H; Suganami T; Konuma K; Marumoto Y; Terai S; Sakugawa H; Kanai S; Hamaguchi M; Fukaishi T; Aoe S; Akiyoshi K; Komohara Y; Takeya M; Sakaida I; Ogawa Y
PLoS One; 2013; 8(12):e82163. PubMed ID: 24349208
[TBL] [Abstract][Full Text] [Related]
7. Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis.
Itoh M; Suganami T; Nakagawa N; Tanaka M; Yamamoto Y; Kamei Y; Terai S; Sakaida I; Ogawa Y
Am J Pathol; 2011 Nov; 179(5):2454-63. PubMed ID: 21906580
[TBL] [Abstract][Full Text] [Related]
8. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH.
Shiba K; Tsuchiya K; Komiya C; Miyachi Y; Mori K; Shimazu N; Yamaguchi S; Ogasawara N; Katoh M; Itoh M; Suganami T; Ogawa Y
Sci Rep; 2018 Feb; 8(1):2362. PubMed ID: 29402900
[TBL] [Abstract][Full Text] [Related]
9. Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
Matsumoto M; Yashiro H; Ogino H; Aoyama K; Nambu T; Nakamura S; Nishida M; Wang X; Erion DM; Kaneko M
PLoS One; 2020; 15(1):e0228212. PubMed ID: 31990961
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects.
Kawakubo M; Tanaka M; Ochi K; Watanabe A; Saka-Tanaka M; Kanamori Y; Yoshioka N; Yamashita S; Goto M; Itoh M; Shirakawa I; Kanai S; Suzuki H; Sawada M; Ito A; Ishigami M; Fujishiro M; Arima H; Ogawa Y; Suganami T
Sci Rep; 2020 Jan; 10(1):983. PubMed ID: 31969650
[TBL] [Abstract][Full Text] [Related]
11. The modulation of hepatic adenosine triphosphate and inflammation by eicosapentaenoic acid during severe fibrotic progression in the SHRSP5/Dmcr rat model.
Jia X; Naito H; Yetti H; Tamada H; Kitamori K; Hayashi Y; Yamagishi N; Wang D; Yanagiba Y; Ito Y; Wang J; Tanaka N; Ikeda K; Yamori Y; Nakajima T
Life Sci; 2012 Jun; 90(23-24):934-43. PubMed ID: 22569299
[TBL] [Abstract][Full Text] [Related]
12. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
13. A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH.
Fraser DA; Wang X; Lund J; Nikolić N; Iruarrizaga-Lejarreta M; Skjaeret T; Alonso C; Kastelein JJP; Rustan AC; Kim YO; Schuppan D
J Hepatol; 2022 Apr; 76(4):800-811. PubMed ID: 34915054
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative.
Stokman G; van den Hoek AM; Denker Thorbekk D; Pieterman EJ; Skovgård Veidal S; Basta B; Iruarrizaga-Lejarreta M; van der Hoorn JW; Verschuren L; Berbée JFP; Rensen PCN; Skjaeret T; Alonso C; Feigh M; Kastelein JJP; Friedman SL; Princen HMG; Fraser DA
Liver Int; 2020 Nov; 40(11):2860-2876. PubMed ID: 32841505
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
[TBL] [Abstract][Full Text] [Related]
16. Development of a non-alcoholic steatohepatitis model with rapid accumulation of fibrosis, and its treatment using mesenchymal stem cells and their small extracellular vesicles.
Watanabe T; Tsuchiya A; Takeuchi S; Nojiri S; Yoshida T; Ogawa M; Itoh M; Takamura M; Suganami T; Ogawa Y; Terai S
Regen Ther; 2020 Jun; 14():252-261. PubMed ID: 32455155
[TBL] [Abstract][Full Text] [Related]
17. Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice.
Suzuki-Kemuriyama N; Matsuzaka T; Kuba M; Ohno H; Han SI; Takeuchi Y; Isaka M; Kobayashi K; Iwasaki H; Yatoh S; Suzuki H; Miyajima K; Nakae D; Yahagi N; Nakagawa Y; Sone H; Yamada N; Shimano H
PLoS One; 2016; 11(6):e0157580. PubMed ID: 27333187
[TBL] [Abstract][Full Text] [Related]
18. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation.
Chung HK; Kim YK; Park JH; Ryu MJ; Chang JY; Hwang JH; Lee CH; Kim SH; Kim HJ; Kweon GR; Kim KS; Shong M
Liver Int; 2015 Apr; 35(4):1341-53. PubMed ID: 25443620
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.
Pizarro M; Solís N; Quintero P; Barrera F; Cabrera D; Rojas-de Santiago P; Arab JP; Padilla O; Roa JC; Moshage H; Wree A; Inzaugarat E; Feldstein AE; Fardella CE; Baudrand R; Riquelme A; Arrese M
Liver Int; 2015 Sep; 35(9):2129-38. PubMed ID: 25646700
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
